Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Dry and Wet Age-Related Macular Degeneration – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of AMD comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of AMD for each country, as…
Dry and Wet Age-Related Macular Degeneration – Epidemiology – Extrapolated Worldwide Coverage
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key AMD patient populations covering 171 countries and more than 99% of…
Dry and Wet Age-Related Macular Degeneration | Treatment Algorithms: Claims Data Analysis | Wet Age-Related Macular Edema | US | 2022
MARKET OUTLOOK Age-related macular degeneration (AMD) is a leading cause of visual impairment in the United States, and more than half of advanced AMD patients have the wet (exudative,…
Dry and Wet Age-Related Macular Degeneration | Disease Landscape & Forecast | G7 | 2021
The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors—Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis,…
